MVM Life Science Partners
- Company typePrivate
- Founded1997
- HeadquartersLondon, United Kingdom
- Headcount11–50
- GTM typeB2B
- OfferingServices
MVM Life Science Partners firmographics
Firmographics- Name
- MVM Life Science Partners
- Legal name
- MVM Partners LLP
- Website
- http://mvm.com
- Company type
- Private
- Founded year
- 1997
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Ownership category
- akta.pro rank
MVM Life Science Partners industry classification
Industry- Product category
- Healthcare Private Equity
- NAICS
- Portfolio Management and Investment Advice (523940), Portfolio Management and Investment Advice (52394)
- SIC
- Security Brokers, Dealers & Flotation Companies (6211)
- akta.pro primary industry
- Corporate Strategic Partnership & Ecosystem Investment Arms (FSANAHAF)
Keywords
Where MVM Life Science Partners is headquartered
LocationHeadquarters
- HQ city
- London
- HQ country
- United Kingdom
- HQ region
- Europe
Offices3 records
Markets served
MVM Life Science Partners business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Personnel, Operations, Marketing or Sales, Others
Revenue model
- Private Equity Fund Management: MVM generates returns through equity investments in healthcare companies, partnering with management teams to build world-class companies and achieve successful exits through acquisitions and IPOs. The firm has completed 42 exits since founding in 1997.
- Portfolio Company Returns: Investment returns realized through exits - recent notable exits include Nalu Medical (acquired by Boston Scientific for ~$533M in 2025), Optinose (acquired by Paratek), and other strategic acquisitions.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Other | Multi-year contract | Fund Management |
Go-to-market motion1 record
Distribution channels1 record
Marketing channels3 records
MVM Life Science Partners product offering
Product offeringCore offering
MVM Partners LLP provides growth-stage equity capital and strategic partnership to healthcare companies with high growth potential, investing $20-100 million aggregate per portfolio company across medical technology, pharmaceuticals, diagnostics, contract research and manufacturing, digital health, and other healthcare sectors. The firm partners with management teams to bring innovative products to market, drive growth, execute strategic acquisitions, and establish new standards of care, sourcing return from capital appreciation and exits (acquisitions and IPOs) across its concentrated portfolio.
Product overview
MVM Partners is a life science private equity firm that provides equity investment and strategic support to high-growth healthcare businesses. The firm invests across medical technology, pharmaceuticals, diagnostics, contract research and manufacturing, digital health, and other healthcare sectors. Rather than offering a unified software product, MVM operates as a financial investment partnership that deploys capital in the $20-100 million range per portfolio company, working closely with management teams to accelerate growth and scale innovative healthcare companies. The firm's portfolio includes companies such as GT Medical Technologies (GammaTile radiation therapy for brain tumors), Neurent Medical (NEUROMARK System for chronic rhinitis), ProVerum (ProVee System for BPH), Avanzanite (rare disease pharmaceutical distribution), and various other medical device and healthcare technology companies.
Differentiator
Problem solved
Functional benefit
Products and services
- MVM Private Equity Investment Services Equity capital and strategic partnership for healthcare companies with high growth potential, investing $20-100 million aggregate per portfolio company across medical technology, pharmaceuticals, diagnostics, contract research and manufacturing, digital health, and other healthcare sectors. Targeted at management teams of growth-stage healthcare businesses with differentiated technology addressing significant unmet needs.
Quantifiable outcome
- 42 successful exits since founding in 1997
- +4 more outcomes
Companies that use MVM Life Science Partners
Customer profileNamed customers4 records
Segments2 records
Ideal customer profiles1 record
MVM Life Science Partners technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature1 record
MVM Life Science Partners partnerships and signals
Strategic signalScale indicators5 records
Recent moves8 records
Expansion highlights5 records
MVM Life Science Partners competitors and assessment
Company assessmentDirect peers
- EQT Life Sciences: EQT Life Sciences (formerly LSP) is a healthcare-focused growth equity firm based in the Netherlands, investing across medical devices, pharma, and diagnostics across Europe and the US — directly comparable to MVM in stage focus, check size, and European-US footprint.
- Sofinnova Partners: Paris-based Sofinnova is one of Europe's largest healthcare-only venture capital firms with €4B+ AUM, investing across medtech, biotech, and digital health from early to late stage — a near-direct peer that has co-invested alongside MVM in Neurent Medical.
- Gilde Healthcare Partners: Dutch healthcare-focused PE/VC firm investing in medtech, therapeutics, and digital health across Europe and the US — directly comparable to MVM in sector focus and stage, and a recurring co-investor (ProVerum, GT Medical).
- Forbion: Forbion is a leading European healthcare-dedicated VC firm with multi-billion AUM, investing across pharma, medtech, and digital health from seed to late-stage — directly comparable to MVM in sector mandate and transatlantic coverage.
- OrbiMed: OrbiMed is one of the world's largest healthcare-dedicated investment firms with $17B+ AUM across venture, growth, and public strategies — a direct sector peer that co-invested with MVM in ProVerum's Series B.
- Abingworth: Abingworth is a UK-headquartered healthcare-only investment firm with global reach, investing across all stages of therapeutics, medtech, and digital health — comparable to MVM in sector specialization, geography, and stage range.
- Ampersand Capital Partners: Ampersand is a Boston-based healthcare and life sciences-focused PE firm investing in pharma services, medical devices, and specialty healthcare — directly comparable to MVM in sector focus and check size.
- Atlas Venture: Atlas Venture is a Boston/Cambridge-based early-stage venture firm focused on biotech and healthcare — comparable to MVM in healthcare-only mandate, though biased toward earlier stages.
Broad incumbents
- Novo Holdings (Novo Ventures): Novo Holdings manages the Novo Nordisk Foundation's investment portfolio with substantial healthcare/biotech allocations globally — a broader incumbent that competes for similar deals but with a much larger capital base and broader sector mandate.
- Bain Capital Life Sciences: Bain Capital Life Sciences is a dedicated healthcare investment platform within Bain Capital, deploying large growth and buyout capital across therapeutics, medtech, and healthcare services — a broader incumbent competing for the same healthcare innovation deals as MVM.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key risks6 records
Key highlights7 records
Customer concentration
MVM Life Science Partners social profiles
Digital presenceMVM Life Science Partners compliance and trust
Trust signalCompliance1 record
MVM Life Science Partners financial estimates
Financial estimateRevenue estimate
Valuation estimate
MVM Life Science Partners leadership team
Management profileNumber of profiles
Profiles20 records
MVM Life Science Partners funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
MVM Life Science Partners M&A and investment
M&A and investmentM&A
Investments89 records
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about MVM Life Science Partners
What does MVM Life Science Partners do?
MVM Partners LLP provides growth-stage equity capital and strategic partnership to healthcare companies with high growth potential, investing $20-100 million aggregate per portfolio company across medical technology, pharmaceuticals, diagnostics, contract research and manufacturing, digital health, and other healthcare sectors. The firm partners with management teams to bring innovative products to market, drive growth, execute strategic acquisitions, and establish new standards of care, sourcing return from capital appreciation and exits (acquisitions and IPOs) across its concentrated portfolio.
Is MVM Life Science Partners a public or private company?
MVM Life Science Partners is a private company. It is classified as management employee owned and is currently operating.
When was MVM Life Science Partners founded?
MVM Life Science Partners was founded in 1997. It employs 11 to 50 people.
Where is MVM Life Science Partners based?
MVM Life Science Partners is headquartered in London, United Kingdom, in the Europe region.
How does MVM Life Science Partners make money?
Two revenue lines are on record. Private Equity Fund Management is the primary driver. The others are portfolio Company Returns.
Who are MVM Life Science Partners's main competitors?
Direct peers on record are EQT Life Sciences, Sofinnova Partners, Gilde Healthcare Partners, Forbion, OrbiMed, Abingworth, Ampersand Capital Partners and Atlas Venture. Broad incumbents are Novo Holdings (Novo Ventures) and Bain Capital Life Sciences.
Does MVM Life Science Partners have an API?
No public API is recorded for MVM Life Science Partners.
What industry is MVM Life Science Partners in?
MVM Life Science Partners's product category is Healthcare Private Equity. Its primary akta.pro industry code is FSANAHAF, Corporate Strategic Partnership & Ecosystem Investment Arms. Its NAICS code is 523940 and its SIC code is 6211.